NCT06886971 Strategies to AchieVe Viral Suppression for Youth With HIV
| NCT ID | NCT06886971 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Human Immunodeficiency Virus (HIV) Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 288 participants |
| Start Date | 2024-11-10 |
| Primary Completion | 2027-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 288 participants in total. It began in 2024-11-10 with a primary completion date of 2027-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other populations likely related to multi-layered challenges (social determinants, cognitive development), system, and biomedical challenges including the reliance on oral ART as the only choice for HIV treatment. Given that approximately 1/3 of AHIV despite being in care fail to attain or sustain VS with resultant individual and public health risk, there is a need to develop real-world implementable interventions that can improve the participants virologic outcomes. The Strategies to AchieVe Viral Suppression for Youth with HIV (SAVVY) Study aims to 1) optimize personal ART choice by using the HIV-ASSIST clinical program to inform CHOICE counseling regarding an AHIV's preferred approach, including the possibility of long-acting injectable ART (LAI-ART); 2) facilitate access to the participants preferred choice through deploying a focused team to navigate barriers to attaining LAI-ART; and 3) decipher and address the patient, provider, and systemic barriers to the uptake and routinization of LAI-ART among AHIV by applying an implementation science framework and assessing cost-effectiveness providing critical data to support comprehensive approaches to optimizing ART and VS for AHIV, a key population identified in the Ending the HIV Epidemic in the United States Initiative.
Eligibility Criteria
Inclusion Criteria: * prescribed ART, * willing to sign informed consent (including communication with one's primary HIV provider) Exclusion Criteria: * Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV) * disallowed medications, * pregnancy. * Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation; * severe illness/hospitalization at the time of enrollment, * plan to move away in the next 12 months.
Contact & Investigator
Allison Agwu, MD, SCM
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT06886971 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 30 Years, studying Human Immunodeficiency Virus (HIV) Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06886971 currently recruiting?
Yes, NCT06886971 is actively recruiting participants. Contact the research team at ageorg10@jhmi.edu for enrollment information.
Where is the NCT06886971 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06886971 clinical trial?
NCT06886971 is sponsored by Johns Hopkins University. The principal investigator is Allison Agwu, MD, SCM at Johns Hopkins University. The trial plans to enroll 288 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.